[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352697-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352697-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","bpgm-as-an-intrinsic-brake-to-constrain-metastasis-through-phospho-epigenetic-mediated-carnitine-biosynthesis-suppression","BPGM as an intrinsic brake to constrain metastasis through phospho-epigenetic-mediated carnitine biosynthesis suppression","","Metastatic dissemination depends on metabolic rewiring, yet intrinsic metabolic “brakes” that restrain progression remain unclear. Bisphosphoglycerate mutase (BPGM) is identified as a metastasis suppressor linking glycolytic flux to carnitine-dependent fatty acid oxidation. High-resolution metabolomics reveals a BPGM–2,3-BPG metabolic checkpoint whose disruption predicts metastatic virulence in multiple cancers. Mechanistically, BPGM promotes CDK1-T14 phosphorylation-driven formation of an EZH2-H3K27me3 repressor that silences BBOX1, limiting carnitine biosynthesis. Hypoxia-activated KDM4A-H3K9me3 cascade inactivates this checkpoint, enabling metastatic potential, while BBOX1 inhibition using Meldonium replicates suppression in orthotopic models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bpgm-as-an-intrinsic-brake-to-constrain-metastasis-through-phospho-epigenetic-mediated-carnitine-biosynthesis-suppression/352697/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bpgm-as-an-intrinsic-brake-to-constrain-metastasis-through-phospho-epigenetic-mediated-carnitine-biosynthesis-suppression/352697.png","ImageObject",300,407,{"name":42,"@type":43},"Sophia Brooks","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does BPGM play in tumor metastasis?","Question",{"text":63,"@type":64},"BPGM acts as a metastasis suppressor that limits metastatic progression by coordinating a phospho-epigenetic pathway controlling carnitine-dependent fatty acid oxidation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does BPGM mechanistically suppress metastasis?",{"text":68,"@type":64},"BPGM triggers CDK1-T14 phosphorylation-dependent assembly of an EZH2-H3K27me3 repressor complex that silences BBOX1, the rate-limiting enzyme for carnitine biosynthesis.",{"name":70,"@type":61,"acceptedAnswer":71},"Why does hypoxia enhance metastatic potential in this framework?",{"text":72,"@type":64},"Hypoxia-mediated KDM4A-H3K9me3 cascade inactivates the BPGM-linked metabolic-epigenetic checkpoint, releasing metastatic potential by disrupting the brake on carnitine-fueled progression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352697,1790181736,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Neoplasia 75 (2026) 101299  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>BPGM as an intrinsic brake to constrain metastasis through phospho-epigenetic-mediated carnitine biosynthesis suppression\u003Cbr>Meng-Zhi Wu a,b,1 , Dou Feng a,b,c,1, Wu-Ping Liu a,b,\u003Cbr>Wei-Lun Huang a,b,c, Qiang Wu a,b,c, Tian-Sheng Chou a,b, Wen-Hao Xiao a,b,c,\u003Cbr>Zhou-Zhou Yao a,b,c, Zhen-Jiang Lia,b,c, Ting-Ting Xiea,b,d, Chang-Han Chena,b, Zhi-Yu Yanga,b, Rui-Wen Mao a,b, Ci-Chun Wu a,b,e, Jun-Cheng Wang a,b,c, Yu-Jin Zhang a,b, Rodney E Kellemsf, Yang Xia a,b,c,*\u003Cbr>a National Medical Metabolomics International Collaborative Research Center, Xiangya Hospital, Central South University, Changsha, Hunan, China\u003Cbr>b National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China c Depatment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China d Department of Family Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China\u003Cbr>e Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China\u003Cbr>f Department of Biochemistry and Molecular Biology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA |  |  | |\n| --- | --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords: Bisphosphoglycerate mutase Tumor metastasis Carnitine biosynthesis\u003Cbr>γ-butyrobetaine hydroxylase (BBOX1) Histone methylation |  | Metabolic adaptations that fuel metastatic dissemination are increasingly mapped, yet the existence of intrinsic metabolic \"brakes\" that actively restrain metastatic progression remains enigmatic. Here, we unveil bisphosphoglycerate mutase (BPGM) as a previously unrecognized metastasis suppressor that orchestrates a phosphoepigenetic relay linking glycolytic flux to carnitine-dependent fatty acid oxidation. Through high-resolution metabolomics, we discover that BPGM and its catalytic product 2,3-bisphosphoglycerate (2,3-BPG) constitute a metabolic checkpoint whose disruption predicts metastatic virulence in multiple cancers. Mechanistically, BPGM suppresses metastasis by triggering CDK1-T14 phosphorylation-dependent assembly of an EZH2-H3K27me3 repressor complex that silences γ-butyrobetaine hydroxylase (BBOX1), the rate-limiting enzyme incarnitine biosynthesis. This phospho-switch mechanism converts glycolytic 2,3-BPG levels into epigenetic orchestrator, thereby starving metastatic cells of carnitine-required fatty acid oxidation. Hypoxia-mediated KDM4A-H3K9me3 cascade emerges as the upstream inactivator of this metabolic-epigenetic checkpoint, explaining how tumor microenvironmental stress liberates metastatic potential. Therapeutically, pharmacological BBOX1 inhibition with Meldonium recapitulates BPGM-mediated metastasis suppression in orthotopic models, reducing metastatic burden. These findings reveal BPGM as a metabolic gatekeeper that integrates bioenergetic sensing with chromatin remodeling to constrain metastatic competence, while hypoxia-mediated checkpoint failure unleashes carnitine-fueled metastatic progression. Targeting the hypoxia-BPGM-BBOX1 axis represents an innovative approach for metastasis-preventive therapy. |  |\n\nIntroduction  \nCancer remains the second leading cause of global mortality, with metastasis driving over 90 % of cancer-associated deaths through a multi-step cascade involving cell migration, invasion, dissemination, and colonization of distant organs [1,2]. Hypoxia-mediated metabolic reprogramming is a well-established hallmark of solid malignant tumors  \nwith high metastasis and mortality rates, including hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC) and melanoma, yet conventional research has largely focused on cell-","cbCaikT7MlcSF3hZ","https://ap.wps.com/l/cbCaikT7MlcSF3hZ","pdf",9923364,16,"English","# Introduction\n## Metastasis and hypoxia-driven metabolic reprogramming\n## Metabolic programming across metastatic stages\n## Targetable metabolic vulnerabilities\n# Article information\n## Keywords and abstract\n## Corresponding authors and publication details","[{\"question\":\"What role does BPGM play in tumor metastasis?\",\"answer\":\"BPGM acts as a metastasis suppressor that limits metastatic progression by coordinating a phospho-epigenetic pathway controlling carnitine-dependent fatty acid oxidation.\"},{\"question\":\"How does BPGM mechanistically suppress metastasis?\",\"answer\":\"BPGM triggers CDK1-T14 phosphorylation-dependent assembly of an EZH2-H3K27me3 repressor complex that silences BBOX1, the rate-limiting enzyme for carnitine biosynthesis.\"},{\"question\":\"Why does hypoxia enhance metastatic potential in this framework?\",\"answer\":\"Hypoxia-mediated KDM4A-H3K9me3 cascade inactivates the BPGM-linked metabolic-epigenetic checkpoint, releasing metastatic potential by disrupting the brake on carnitine-fueled progression.\"}]","BPGM as an intrinsic brake to constrain metastasis through phospho-epigenetic-mediated carnitine biosynthesis suppression | PDF",1790100943,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd0f27745dc0f98c42247875a25fe148.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a2b0bbe4a64e0aa3a84ab0bcd52b155.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3c685d72345a3e0becfaf48480fb0e5.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3409aebd4e544c62445d4ad8761e20c3.webp",980,1306]